Insmed Incorporated Announced Q1 2026 Earnings on May 7, 2026, Reporting "in the first 2 full quarters, we've done $350 million of revenue".

Insmed Incorporated reported its first quarter 2026 financial results, noting that "cost of product revenues in the first quarter of 2026 was $47.4 million or 15.5% of revenues". Management highlighted its cash position, stating that as of the end of the first quarter of 2026, the company had approximately $1.2 billion in cash, cash equivalents and marketable securities.

Executives expressed confidence in the company's financial trajectory, stating they "would expect to achieve sustainable cash flow positivity in 2027" without requiring additional capital to support their existing business.

During the quarter, management stated that "BRINSUPRI's launch continues to exceed our expectations," delivering 44% sequential growth.

The company noted strong payer access, with an approval rate of nearly 90% for patients processed through specialty pharmacies since launch.

Additionally, more than 80% of patients on the therapy have enrolled in the inLighten patient support program.

Insmed also launched Suspect BE, a new diagnosis-focused disease education campaign aimed at raising awareness and proper diagnosis of bronchiectasis.In clinical updates, Insmed plans to submit data from the Phase 3b ENCORE study of ARIKAYCE to regulatory authorities in the U.S. and Japan in the second half of the year.

The company also advanced its TPIP pipeline, opening the first site for the Phase 3 PALM PAH study and anticipating data from a Phase 2b open-label extension study in the third quarter of this year.

Looking forward, the company reiterated its full year 2026 revenue guidance of "at least $1 billion" for BRINSUPRI.